WLPretty much a safe bet (possibly) but let's look at it another...

WL

Pretty much a safe bet (possibly) but let's look at it another way.

Say this a precursor to a CR with ability (maybe) to get to the stage the concept and initial results by say end of yr support potential for trials.

Given we would believe AVE management understand the requirements and costs of clinical trials and also the unlikely ability of AVE to undertake themselves, is it not also conceivable that another larger entity in the medicinal marijuana space comes on board to fund the later stages?

Especially if by reading the AGM presso we glean they expect pharma grade will become more the preferred product and that companies in this space will want to get that to market and if TPM does prove advantageous and patentable then provides that point of difference as indicated.

Just a diff thought process on a longer time horizon.